April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Non-Viral Sleeping Beauty-Mediated Transfection of Retinal Pigment Epithelial Cells
Author Affiliations & Notes
  • Anna Dobias
    Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany
  • Mattia Ronchetti
    IGEA, Carpi, Italy
  • Ruggero Cadossi
    IGEA, Carpi, Italy
  • Peter Walter
    Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany
  • Gabriele Thumann
    Département des neurosciences cliniques, Hôpitaux universitaires de Genève, Genève, Switzerland
  • Sandra Johnen
    Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany
  • Footnotes
    Commercial Relationships Anna Dobias, None; Mattia Ronchetti, None; Ruggero Cadossi, None; Peter Walter, None; Gabriele Thumann, None; Sandra Johnen, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1827. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anna Dobias, Mattia Ronchetti, Ruggero Cadossi, Peter Walter, Gabriele Thumann, Sandra Johnen; Non-Viral Sleeping Beauty-Mediated Transfection of Retinal Pigment Epithelial Cells. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1827.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: In neovascular age-related macular degeneration (AMD), which leads to severe vision loss within several months, the growth of choroidal blood vessels into the subretinal space is caused by an increase of the pro-angiogenic vascular endothelial growth factor (VEGF) and a decrease of the anti-angiogenic pigment epithelium-derived factor (PEDF). The current treatment with anti-VEGF antibodies improves vision in about 30% of patients, but may be accompanied by severe side effects and non-compliance. To increase the level of PEDF in the subretinal space, we proposed the subretinal transplantation of pigment epithelial cells genetically modified to stably overexpress PEDF. Since transgene delivery using viral vectors is complicated by immune responses, viral spread, and transgene introduction into unwanted cells, we have developed a transfection protocol that uses the non-viral Sleeping Beauty (SB100X) transposon system.

Methods: Primary human retinal pigment epithelial (RPE) cells were transfected with plasmids encoding the SB100X transposase and the Venus reporter gene using the pipette tip-based Neon Transfection System (Life Technologies) or the cuvette-based CliniporatorTM System (IGEA, Italy). Transfection efficiency and transgene expression stability were evaluated by fluorescence microscopy and flow cytometric analysis

Results: Using the Neon Transfection System, increasing electric field parameters ranging from 1100 to 1350 V / 20 to 30 ms / 2 pulses resulted in increased numbers of transfected cells (14.8 ± 20.1% to 28.1 ± 19.7%), stable for the 12 months that the cells have been cultured. With the CliniporatorTM System, best transfection efficiencies were observed with a combination of high (150 V / 0.1 ms / 7 pulses) and low (40 V / 20 ms / 2 pulses) voltage pulses.

Conclusions: SB100X-mediated transfection by electroporation is efficient and stable for primary human RPE cells. In contrast to the Neon Transfection System, the CliniporatorTM System allows for quality control of the electroporation process, which is essential for the development of a transposon-based gene therapeutic approach.

Keywords: 412 age-related macular degeneration • 538 gene transfer/gene therapy • 701 retinal pigment epithelium  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.